公司資料
Vericel Corp 股價、新聞與催化劑
- 股票代碼:
- VCEL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
42.68 USD (+1.35%)
收盤價
最後更新: 2026年8月21日
1.76B USD
市值
股價為何變動
As of Aug 21, 2026, VCEL closed up 1.35% at $42.68. No new same-company headline was identified in the current news window.
公司概覽
Advanced Therapies for Sports Medicine and Burns
Vericel is a commercial-stage advanced therapies company serving the sports medicine and severe burn care markets. Its portfolio combines cell therapies and specialty biologics aimed at repairing injuries and restoring function.
MACI-Led Sports Medicine Franchise
MACI is Vericel's largest product and core growth driver. It is an autologous cellularized scaffold product used to repair symptomatic full-thickness cartilage defects of the knee in adults. Second-quarter 2026 MACI revenue grew 23%, supported by double-digit biopsy and implant growth and record second-quarter surgeon and procedure metrics.
Severe Burn Care Portfolio
Vericel's burn care business includes Epicel, a permanent skin replacement for severe burns, and NexoBrid, a biologic used for eschar removal in deep partial-thickness and full-thickness thermal burns. The burn care franchise grew 22% in the second quarter, with NexoBrid posting record quarterly revenue.
Strategic Position
Vericel is best understood as a profitable, commercial advanced-therapy company with two focused procedural franchises. Its differentiation comes from specialized biologic products, surgeon adoption, manufacturing scale, and clinical use in high-need repair settings.
未來催化劑
- MACI marketing authorization review in the United Kingdom.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。